CRBP - コ―バス・ファ―マシュ―ティカルズ (Corbus Pharmaceuticals Holdings Inc.) コ―バス・ファ―マシュ―ティカルズ

 CRBPのチャート


 CRBPの企業情報

symbol CRBP
会社名 Corbus Pharmaceuticals Holdings Inc (コ―バス・ファ―マシュ―ティカルズ)
分野(sector) Health Care   ヘルスケア
産業(industry) Major Pharmaceuticals  
業種 バイオテクノロジ―_メディカルリサ―チ   医療関連(Health Care)
概要 事業概要 コールバス・ファーマシューティカルズ・ホールディングス(Corbus Pharmaceuticals Holdings Inc.)は臨床段階の製薬会社である。同社は希少・慢性・深刻炎症性及び線維性疾患を治療するための治療薬の開発・商品化に焦点を当てる。同社は希少な生命を脅かす炎症性線維症疾患の治療薬の開発・商品化を通じて事業を運営する。同社の製品であるlenabasumは慢性炎症を解消し、線維化過程を止めるように設計された合成経口エンドカンナビノイド模倣薬である。lenabasumは内因性経路を活性化することによって炎症を解消し、線維化を停止させるように作用する専門化されたプロ解消脂質メディエーター(SPM)の生産を促進する。同社は全身性硬化症、嚢胞性線維症、びまん性皮膚疾患、皮膚優性皮膚筋炎及び全身性エリテマトーデス(SLE)の4つの疾患を治療するためのlenabasumを開発する。   コ―バス・ファ―マシュ―ティカルズは炎症性線維症の治療薬の開発と商品化に焦点を置く米国のバイオ医薬品会社。第2相臨床試験を行う「リスナブ」は嚢胞性線維症と硬皮症の治療用の経口抗炎症剤。「リスナブ」はカンナビノイド受容体(CB2)を活性化し、抗炎性物質の放出を促進するとともに、炎症性物質の放出とサイトカインの分泌を抑制。   Corbus Pharmaceuticals Holdings, Inc. is a phase 3 clinical-stage pharmaceutical company, which focuses on the development and commercialization of novel therapeutics to treat rare, chronic, and serious inflammatory and fibrotic diseases. The Company's lead product candidate, lenabasum, is a novel, synthetic oral endocannabinoid-mimetic drug designed to resolve chronic inflammation and fibrotic processes. Lenabasum is currently being evaluated in systemic sclerosis, cystic fibrosis, dermatomyositis, and systemic lupus erythematosus. The company was founded on December 18, 2013 and is headquartered in Norwood, MA.
本社所在地 500 River Ridge Drive Norwood MA 02062 USA
代表者氏名 Mark A. Tepper マークA.テッパー
代表者役職名 President Chief Scientific Officer
電話番号 +1 617-963-0103
設立年月日
市場名 NASDAQ National Market System
ipoyear ―年
従業員数 47人
url www.corbuspharma.com
nasdaq_url https://www.nasdaq.com/symbol/crbp
adr_tso
EBITDA EBITDA(百万ドル) -41.67992
終値(lastsale) 6.79
時価総額(marketcap) 388429351.1
時価総額 時価総額(百万ドル) 396.43820
売上高 売上高(百万ドル) 2.60040
企業価値(EV) 企業価値(EV)(百万ドル) 331.84536
当期純利益 当期純利益(百万ドル) -41.42403
決算概要 決算概要 BRIEF: For the six months ended 30 June 2018 Corbus Pharmaceuticals Holdings Inc revenues increased 10% to $1.8M. Net loss increased 61% to $23.8M. Revenues reflect an increase in demand for the Company's products and services due to favorable market conditions. Higher net loss reflects Research and development increase of 65% to $20M (expense) General and administrative increase of 42% to $6M (expense).

 CRBPのテクニカル分析


 CRBPのニュース

   Corbus Pharmaceuticals Reports Last Subject Visit in Phase 2b Study of Lenabasum for Treatment of Cystic Fibrosis  2020/06/22 12:05:00 GlobeNewswire
Topline data on schedule for Q3 2020Reduction in pulmonary exacerbations (PEx) as primary endpoint Study enrolled 426 participants regardless of CFTR…
   Cannabis Stock Gainers And Losers From June 17, 2020  2020/06/17 21:08:17 Benzinga Feeds
Gainers AusCann Group Holdings (OTC: ACNNF ) shares closed up 9.17% at $0.1 Heritage Cannabis Holding (OTC: HERTF ) shares closed up 7.56% at $0.10 Delta 9 Cannabis (OTC: VRNDF ) shares closed up 5.2% at $0.40 High Tide (OTC: HITIF ) shares closed up 5.2% at $0.14 Corbus Pharmaceuticals (NASDAQ: Full story available on Benzinga.com
   Cannabis Stock Gainers And Losers From June 16, 2020  2020/06/16 22:34:39 Benzinga Feeds
Gainers Axim Biotechnologies (OTC: AXIM ) shares closed up 11.23% at $0.34 Zynerba Pharmaceuticals (NASDAQ: ZYNE ) shares closed up 8.61% at $5.49 GTEC Holdings (OTC: GGTTF ) shares closed up 8.38% at $0.14 Zenabis Global (OTC: ZBISF ) shares closed up 6.65% at $0.11 Canopy Gwth (NYSE: CGC ) shares closed up 6.45% at $17.82 Corbus Pharmaceuticals (NASDAQ: CRBP ) shares closed up 6.09% at $7.58 Cansortium (OTC: CNTMF ) shares … Full story available on Benzinga.com
   Is Corbus Pharmaceuticals (CRBP) Stock a Solid Choice Right Now?  2020/06/01 13:00:00 Zacks Investment Research
Corbus Pharmaceuticals (CRBP) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.
   The Daily Biotech Pulse: Cumberland's Positive Anti-Bacterial Readout, FDA Nods For Bristol-Myers, Astellas  2020/05/27 11:25:23 Benzinga
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs May 26) ADC Therapeutics SA (NYSE: ADCT ) (IPOed May 15) Aeglea Bio Therapeutics Inc (NASDAQ: AGLE )(announced positive one-year Phase 1/2 study and Phase 2 open-label extension study of pegzilarginase in Arginase 1 Deficiency patients) Allogene Therapeutics Inc (NASDAQ: ALLO ) Altimmune Inc (NASDAQ: ALT ) argenx SE – ADR (NASDAQ: ARGX )( announced positive top-line data from a late-stage study of efgartigimod in patients with generalized Myasthenia Gravis) BioMarin Pharmaceutical Inc. (NASDAQ: BMRN )(gained on sell-side comment on the company being a potential target for Sanofi SA (NASDAQ: SNY ) Bio-Rad Laboratories, Inc. (NYSE: BIO ) Castle Biosciences Inc (NASDAQ: CSTL ) Catalent Inc (NYSE: CTLT ) ChemoCentryx Inc (NASDAQ: CCXI ) Corbus Pharmaceuticals Holdings Inc (NASDAQ: CRBP ) Cue Biopharma Inc (NASDAQ: CUE ) Evoke Pharma Inc (NASDAQ: EVOK ) Fate Therapeutics Inc (NASDAQ: FATE ) GENMAB A/S/S ADR (NASDAQ: GMAB ) Harpoon Therapeutics Inc (NASDAQ: HARP ) Horizon Therapeutics PLC (NASDAQ: HZNP ) Immunomedics, Inc.
   Is Corbus Pharmaceuticals (CRBP) Stock a Solid Choice Right Now?  2020/06/01 13:00:00 Zacks Investment Research
Corbus Pharmaceuticals (CRBP) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.
   The Daily Biotech Pulse: Cumberland's Positive Anti-Bacterial Readout, FDA Nods For Bristol-Myers, Astellas  2020/05/27 11:25:23 Benzinga
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs May 26) ADC Therapeutics SA (NYSE: ADCT ) (IPOed May 15) Aeglea Bio Therapeutics Inc (NASDAQ: AGLE )(announced positive one-year Phase 1/2 study and Phase 2 open-label extension study of pegzilarginase in Arginase 1 Deficiency patients) Allogene Therapeutics Inc (NASDAQ: ALLO ) Altimmune Inc (NASDAQ: ALT ) argenx SE – ADR (NASDAQ: ARGX )( announced positive top-line data from a late-stage study of efgartigimod in patients with generalized Myasthenia Gravis) BioMarin Pharmaceutical Inc. (NASDAQ: BMRN )(gained on sell-side comment on the company being a potential target for Sanofi SA (NASDAQ: SNY ) Bio-Rad Laboratories, Inc. (NYSE: BIO ) Castle Biosciences Inc (NASDAQ: CSTL ) Catalent Inc (NYSE: CTLT ) ChemoCentryx Inc (NASDAQ: CCXI ) Corbus Pharmaceuticals Holdings Inc (NASDAQ: CRBP ) Cue Biopharma Inc (NASDAQ: CUE ) Evoke Pharma Inc (NASDAQ: EVOK ) Fate Therapeutics Inc (NASDAQ: FATE ) GENMAB A/S/S ADR (NASDAQ: GMAB ) Harpoon Therapeutics Inc (NASDAQ: HARP ) Horizon Therapeutics PLC (NASDAQ: HZNP ) Immunomedics, Inc.
   Corbus Pharmaceuticals (CRBP) Moves to Buy: Rationale Behind the Upgrade  2020/05/15 16:00:14 Zacks Investment Research
Corbus Pharmaceuticals (CRBP) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
   Do Options Traders Know Something About Corbus Pharmaceuticals (CRBP) Stock We Don't?  2020/05/14 13:30:00 Zacks Investment Research
Investors need to pay close attention to Corbus Pharmaceuticals (CRBP) stock based on the movements in the options market lately.
   Cannabis Stock Gainers And Losers From April 9, 2020  2020/04/09 21:35:27 Benzinga Feeds
Gainers The Flowr (OTC: FLWPF ) shares closed up 18.98% at $0.44 NexTech AR Solns (OTC: NEXCF ) shares closed up 19.26% at $1.12 Neptune Wellness Solns (NASDAQ: NEPT ) shares closed up 14.84% at $1.47 Pyxus International (NYSE: PYX ) shares closed up 11.66% at $2.79 Corbus Pharmaceuticals (NASDAQ: CRBP ) shares closed up 9.94% at $5.75 Innovative Industrial (NYSE: … Full story available on Benzinga.com
   Earnings Preview: Corbus Pharmaceuticals (CRBP) Q4 Earnings Expected to Decline  2020/03/03 17:30:31 Zacks Investment Research
Corbus Pharmaceuticals (CRBP) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
   The Daily Biotech Pulse: Merck Goes Shopping, Nuvectra Files For Bankruptcy Protection, Opiant Rips Higher  2019/11/13 12:10:18 Benzinga
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks hitting 52-week highs on Nov. 12) ACADIA Pharmaceuticals Inc (NASDAQ: ACAD ) Allergan plc (NYSE: AGN ) Amgen, Inc. (NASDAQ: AMGN ) Antares Pharma Inc (NASDAQ: ATRS ) Arrowhead Pharmaceuticals Inc (NASDAQ: ARWR ) Bio-Rad Laboratories, Inc. Class A Common Stock (NYSE: BIO ) Bristol-Myers Squibb Co (NYSE: BMY ) Celgene Corporation (NASDAQ: CELG ) Crispr Therapeutics AG (NASDAQ: CRSP ) Diplomat Pharmacy Inc (NYSE: DPLO )( warned of going concern risk) Dicerna Pharmaceuticals Inc (NASDAQ: DRNA ) DexCom, Inc. (NASDAQ: DXCM ) GALAPAGOS NV/S ADR (NASDAQ: GLPG ) Galera Therapeutics Inc (NASDAQ: GRTX ) Insulet Corporation (NASDAQ: PODD ) Karyopharm Therapeutics Inc (NASDAQ: KPTI ) Momenta Pharmaceuticals, Inc. (NASDAQ: MNTA ) Neurocrine Biosciences, Inc. (NASDAQ: NBIX ) Seattle Genetics, Inc. (NASDAQ: SGEN ) Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX ) X T L Biopharmaceuticals Ltd (NASDAQ: XTLB ) XOMA Corp (NASDAQ: XOMA ) Zai Lab Ltd (NASDAQ: ZLAB ) Zimmer Biomet Holdings Inc (NYSE: ZBH ) Down In The Dumps (Biotech stocks hitting 52-week lows on Nov.
   Corbus Pharmaceuticals to Present at the Jefferies 2019 Global Healthcare Conference in London  2019/11/12 13:05:00 Yahoo Finance
- Presentation with live audio webcast on Wednesday, November 20th at 5:20 PM DST - Norwood, MA , Nov. 12, 2019 -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP).
   We Think Corbus Pharmaceuticals Holdings (NASDAQ:CRBP) Can Afford To Drive Business Growth  2019/11/12 12:20:14 Yahoo Finance
Just because a business does not make any money, does not mean that the stock will go down. For example, although…
   The Daily Biotech Pulse: Therapix Calls Off Merger, Alimera's Reverse Split, 2 Biotechs To Debut  2019/11/08 13:14:09 Benzinga
The following is a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech stocks that hit 52-week highs Nov. 7.) Collegium Pharmaceutical Inc (NASDAQ: COLL ) (reacted to third-quarter results released after the market close Wednesday) Deciphera Pharmaceuticals Inc (NASDAQ: DCPH ) DexCom, Inc. (NASDAQ: DXCM ) (reacted to its better-than-expected third-quarter results ) INNATE PHARMA S/S ADR (NASDAQ: IPHA ) Rapt Therapeutics Inc (NASDAQ: RAPT ) (went public Oct. 31) Viela Bio Inc (NASDAQ: VIE ) (went public Oct. 3) XOMA Corp (NASDAQ: XOMA ) Down In The Dumps (Biotech stocks that hit 52-week lows Nov. 7.) Allena Pharmaceuticals Inc (NASDAQ: ALNA ) (reported positive results from two studies evaluating its reloxaliase in high-risk patients with enteric hyperoxaluria and advanced chronic kidney disease) Auris Medical Holding Ltd (NASDAQ: EARS ) bluebird bio Inc (NASDAQ: BLUE ) Caladrius Biosciences Inc (NASDAQ: CLBS ) (reacted to its third-quarter results) CENTOGENE ORD (NASDAQ: CNTG ) (went public Thursday) Cocrystal Pharma Inc (NASDAQ: COCP ) Corbus Pharmaceuticals Holdings Inc (NASDAQ: CRBP ) Helius Medical Technologies Inc (NASDAQ: HSDT ) Infinity Pharmaceuticals Inc.

 関連キーワード  (バイオテクノロジ―_メディカルリサ―チ 米国株 コ―バス・ファ―マシュ―ティカルズ CRBP Corbus Pharmaceuticals Holdings Inc.)

 twitter  (公式ツイッターやCEOツイッターなど)